{"query":"Keytruda pembrolizumab bladder cancer","category":"conventional","results":[{"title":"Advanced Urothelial Bladder Cancer | KEYTRUDA® (pembrolizumab) | Patients","url":"https://www.keytruda.com/advanced-urothelial-bladder-cancer/","snippet":"It may be used alone when your bladder or urinary tract cancer has spread or cannot be removed by surgery (locally advanced or metastatic urothelial cancer), and you have received chemotherapy that contains platinum, and it did not work or is no longer working.","source":"www.keytruda.com","age":""},{"title":"Padcev and Keytruda Double Bladder Cancer Survival - NCI","url":"https://www.cancer.gov/news-events/cancer-currents-blog/2023/bladder-cancer-padcev-keytruda-doubles-survival","snippet":"For the first time in decades, ... trials. One treatment—the combination of enfortumab vedotin (Padcev) and the immunotherapy drug pembrolizumab (Keytruda)—proved to be particularly powerful....","source":"www.cancer.gov","age":""},{"title":"Non-Muscle Invasive Bladder Cancer (NMIBC) - KEYTRUDA® (pembrolizumab) - Patients","url":"https://www.keytruda.com/non-muscle-invasive-bladder-cancer/","snippet":"It may be used alone when your bladder or urinary tract cancer has spread or cannot be removed by surgery (locally advanced or metastatic urothelial cancer), and you have received chemotherapy that contains platinum, and it did not work or is no longer working.","source":"www.keytruda.com","age":""},{"title":"KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery - Merck.com","url":"https://www.merck.com/news/keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-significantly-improved-event-free-and-overall-survival-and-pathologic-complete-response-rate-for-certain-patients-with-muscle/","snippet":"In this study, KEYTRUDA® (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given before and after surgery (radical cystectomy), demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS), the ...","source":"www.merck.com","age":"August 12, 2025"},{"title":"FDA Approves Updated Indication for Merck's KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer) - Merck.com","url":"https://www.merck.com/news/fda-approves-updated-indication-for-mercks-keytruda-pembrolizumab-for-treatment-of-certain-patients-with-urothelial-carcinoma-bladder-cancer/","snippet":"KEYTRUDA Approved for Treatment of Patients With Locally Advanced or Metastatic Urothelial Carcinoma Who Are Not Eligible for Any Platinum-Containing Chemotherapy Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced ...","source":"www.merck.com","age":"March 8, 2025"}]}
{"query":"ETx-22 nectin-4 bladder cancer","category":"pipeline","results":[{"title":"ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors | Cancer Research Communications | American Association for Cancer Research","url":"https://aacrjournals.org/cancerrescommun/article/4/11/2998/750244/ETx-22-a-Novel-Nectin-4-Directed-Antibody-Drug","snippet":"As EV has demonstrated objective responses in locally advanced or metastatic urothelial carcinoma, we compared the antitumor activity of ETx-22 to EV in bladder-derived PDXs. The ETx-22 antitumor effect was higher and more durable than EV in PDX-B521 and PDX-BCLU-003 models, and complete regressions were observed at the ETx-22 dose of 10 mg/kg (Fig. 6C and D). ETx-22 antitumor activity was then tested in TNBC. Treatment was effective and durable in PDX TNBC317 (4 mg/kg) and PDX TNBC348 (1 mg/kg) expressing moderate to low levels of nectin-4 (H-score = 160 and 120, respectively; Fig.","source":"aacrjournals.org","age":"November 1, 2024"},{"title":"ETx-22 » ADC Review","url":"https://www.adcreview.com/drugmap/etx-22-is-an-next-gen-anti-nectin-4-adc/","snippet":"ETx-22 is a next-gen ADC targeting Nectin-4, a protein on the surface of cells that is highly expressed in bladder cancer, TNBC, + others","source":"www.adcreview.com","age":"September 20, 2022"},{"title":"Full article: Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4","url":"https://www.tandfonline.com/doi/full/10.1080/21645515.2025.2504776","snippet":"Lopez M, Crompot E, Josselin E, Farina A, Rubis M, Castellano R, Fares J, Wehbe M, Collette Y, Charafe E, et al. Etx-22, a novel nectin-4–Directed antibody–drug conjugate, demonstrates safety and potent antitumor activity in low-nectin-4–Expressing tumors. Cancer Res Commun.","source":"www.tandfonline.com","age":""},{"title":"News - NECTIN4 underexpression - LARVOL VERI","url":"https://veri.larvol.com/news/nectin4-underexpression/biomarker","snippet":"In contrast, differential Nectin-4 ... chemotherapy. ... ETx-22: a novel nectin-4-directed antibody drug conjugate, demonstrates safety and potent antitumor activity in low nectin-4 expressing tumors....","source":"veri.larvol.com","age":""},{"title":"Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin - PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/34108177/","snippet":"Sensitivity to EV is mediated by expression of NECTIN4, which is enriched in luminal subtypes of bladder cancer. These findings may have implications for biomarker development, patient selection, and the inclusion of molecular subtyping in ongoing ...","source":"pubmed.ncbi.nlm.nih.gov","age":"September 15, 2021"}]}
